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Human immunodeficiency virus (HIV)-positive persons are predisposed to pulmonary infections, even after
receiving effective highly active antiretroviral therapy. The reasons for this are unclear but may involve changes
in innate immune function. HIV type 1 infection of macrophages impairs effector functions, including cytokine
production. We observed decreased constitutive tumor necrosis factor alpha (TNF-) concentrations and
increased soluble tumor necrosis factor receptor type II (sTNFRII) in bronchoalveolar lavage fluid samples
from HIV-positive subjects compared to healthy controls. Moreover, net proinflammatory TNF- activity, as
measured by the TNF-/sTNFRII ratio, decreased as HIV-related disease progressed, as manifested by
decreasing CD4 cell count and increasing HIV RNA (viral load). Since TNF- is an important component of
the innate immune system and is produced upon activation of Toll-like receptor (TLR) pathways, we hypoth-
esized that the mechanism associated with deficient TNF- production in the lung involved altered TLR
expression or a deficit in the TLR signaling cascade. We found decreased Toll-like receptor 1 (TLR1) and TLR4
surface expression in HIV-infected U1 monocytic cells compared to the uninfected parental U937 cell line and
decreased TLR message in alveolar macrophages (AMs) from HIV-positive subjects. In addition, stimulation
with TLR1/2 ligand (Pam3Cys) or TLR4 ligand (lipopolysaccharide) resulted in decreased intracellular phos-
phorylated extracellular signal-regulated kinase and subsequent decreased transcription and expression of
TNF- in U1 cells compared to U937 cells. AMs from HIV-positive subjects also showed decreased TNF-
production in response to these TLR2 and TLR4 ligands. We postulate that HIV infection alters expression of
TLRs with subsequent changes in mitogen-activated protein kinase signaling and cytokine production that
ultimately leads to deficiencies of innate immune responses that predispose HIV-positive subjects to infection.
Pulmonary infections are a major cause of morbidity and mor-
tality during human immunodeficiency virus type 1 (HIV-1) in-
fection (9). In the lung, alveolar macrophages (AMs) are the first
line of defense against pathogens through protective innate im-
mune effector functions, including enhanced microbicidal activity,
phagocytosis, and induction of the proinflammatory cytokine tu-
mor necrosis factor  (TNF-). AMs can be infected by HIV-1;
they express the CD4 and CCR5 coreceptor and are targets for
R5 strains of virus (39). Infection with HIV-1 leads to impaired
effector functions, including alterations in cytokine production
(19), which may play a role in the development of opportunistic
infections (OIs). Highly active antiretroviral therapy (HAART)
has led to a decrease in the incidence of OIs; however, viral
reservoirs persist, and even patients successfully treated with
HAART, along with those failing HAART because of nonadher-
ence or development of drug resistance, are still susceptible to
pulmonary infections, such as tuberculosis, Streptococcus pneu-
moniae pneumonia, and other pulmonary OIs.
Pathogens associated with pulmonary infections activate in-
nate immune responses through interactions with Toll-like re-
ceptor 1 (TLR1), TLR2, TLR4, and TLR6 (26). TLRs are part
of a family of receptors defined by the presence of multiple
leucine-rich repeats in the extracellular domain and an intra-
cellular Toll/interleukin-1 receptor domain; to date, 13 TLRs
have been identified in a variety of cells including monocytes
and macrophages (10, 12). TLR2 forms heterodimers with
other TLRs (e.g., TLR1 or TLR6) to recognize a broad spec-
trum of pathogen-associated molecular patterns that are asso-
ciated with gram-positive bacteria, fungi, and mycobacteria
(30, 36). TLR4 functions as a receptor for gram-negative bac-
terial lipopolysaccharide (LPS) and signals through the coor-
dinated activity of several proteins, including lipid-binding pro-
tein, CD14, and MD2. Receptor engagement triggers complex
TLR- and pathogen-associated molecular pattern-specific sig-
naling cascades. These involve recruitment of adaptor mole-
cules, such as MyD88 to the Toll/interleukin-1 receptor do-
main, serine kinase (IRAK) recruitment and phosphorylation,
intracellular signaling via mitogen-activated protein (MAP)
kinases, subsequent nuclear translocation of transcription fac-
tors, such as NF-B, and upregulation of immediate-early
markers of innate inflammatory responses.
TNF- is a key TLR-induced inflammatory cytokine se-
creted in the lung by AMs. The importance of TNF- in lung
host immunity is highlighted by increased pulmonary infec-
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tions, usually involving Mycobacterium tuberculosis (7) and bac-
terial pathogens, in patients treated with anti-TNF- drugs,
such as infliximab and etanercept (8, 38). Constitutive concen-
trations of TNF- in the lungs of HIV-1-infected individuals or
from AMs exposed ex vivo to bacterial ligands may vary based
on the stage of disease or presence of OIs (17, 33). In this
study, we examined asymptomatic HIV-positive subjects on
stable HAART, HIV-positive individuals on stable HAART
who were failing therapy (based on CD4 and viral load mea-
surements), and healthy HIV-negative control subjects. We
observed decreased constitutive TNF- in bronchoalveolar la-
vage fluid (BALF) samples from HIV-positive subjects com-
pared to HIV-negative controls. This was most pronounced in
HIV-positive subjects with the lowest CD4 cell counts and the
highest HIV RNA (viral load). We also observed that HIV-1-
infected U1 monoblastoid cells, differentiated with phorbol
12-myristate 13-acetate (PMA) to produce an AM-like pheno-
type, showed deficient TNF- production in response to LPS
(the gram-negative bacterial TLR4 ligand) and Pam3Cys (the
synthetic TLR1/TLR2 ligand) compared to uninfected U937
cells. This was associated with decreased TLR surface expres-
sion and changes in the signaling pathways involved in the
secretion of TNF-.
MATERIALS AND METHODS
Study subjects. The study was approved by the Institutional Review Boards of
Boston Medical Center, New England Medical Center, and Beth Israel Deacon-
ess Medical Center. All subjects were volunteers who gave informed consent
before participating in the study. We used a comprehensive questionnaire re-
garding age, sex, smoking status, medical history, including HIV-1 infection,
related infections, and medications. All subjects had no active pulmonary disease
and normal spirometry. We obtained HIV risk factor information, peripheral
blood CD4 count, HIV RNA (viral load) in plasma, history of HIV-related
diseases, and antiretroviral therapy for the HIV-positive subjects who underwent
venipuncture and BAL. All HIV-positive subjects were receiving HAART (sta-
ble HAART for at least the past 8 months).
BALF sample collection and processing. BALF samples and AMs were ob-
tained from subjects by BAL using standard technique (20). All BALF measure-
ments were normalized using the urea correction method, and the data were
expressed as picogram of cytokine or cytokine receptor per milliliter of BALF
sample. The molar ratios of TNF- to soluble tumor necrosis factor receptor type
II (sTNFRII) (p75/CD120b) assumed that three TNF- molecules bind to three
sTNFRII molecules. AMs were separated from the pooled BALF samples by
centrifugation at 100  g for 10 min at 4°C and washed in cold RPMI 1640
(GIBCO Invitrogen Cell Culture, Carlsbad, CA) supplemented with penicillin
(100 U/ml) and streptomycin (100 g/ml) (Sigma, St. Louis, MO). Cells con-
tained 85% to 90% AMs, 10% to 15% lymphocytes, and 1% neutrophils. Cells
demonstrated 98% viability as determined by trypan blue exclusion, were
95% phagocytic of 1.1-mm latex beads, and 95% stained positive for non-
specific esterase.
Culture of cells. BAL cells retrieved from HIV-positive subjects and HIV-
negative healthy volunteers were transferred to 24-well tissue culture plates
(Falcon, Oxnard, CA) at a concentration of 5  105 cells/ml in RPMI 1640
supplemented with penicillin-streptomycin (100 U/ml and 100 g/ml, respec-
tively), amphotericin (0.25 g/ml), L-glutamine (2 mM), HEPES (2 mM; GIBCO
Invitrogen Cell Culture), and 10% fetal calf serum (HyClone, Logan, UT). Cells
were cultured for 16 h; nonadherent cells and supernatant fluids were removed,
and fresh medium was added prior to treatment. The U937 cell line was obtained
from the American Type Culture Collection (ATCC). The U1 cell line (contain-
ing two proviral copies of HIV-1) was obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH, from Thomas
Folks (13). Both U937 and U1 cells were cultured in complete RPMI 1640
supplemented with L-glutamine (2 mM), penicillin-streptomycin (100 U/ml and
100 g/ml, respectively), and 10% fetal bovine serum (GIBCO Invitrogen Cell
Culture). Continuous cell lines were synchronized by passaging 24 h prior to
addition of reagents used for perturbations. U937 and U1 cells were seeded in
24-well plates at a concentration of 1.0  106 cells/ml in a total volume of 2
ml/well.
Reagents. LPS from Escherichia coli 055:B5 (Sigma-Aldrich, St. Louis, MO)
was further purified using a triethylamine and phenol extraction protocol. Cell
lines were pretreated with PMA at a final concentration of 10 nM (Sigma-
Aldrich) for 24 h. Synthetic lipopeptide Pam3Cys-SKKKK x 3HCl (Pam3Cys;
EMC Microcollections GmbH, Germany) was used as a specific TLR2 ligand
(36). Inhibition of extracellular signal-regulated kinase (ERK) phosphorylation
was performed using 2-amino-3-methoxyflavone, PD98059, which acts through
selective and cell-permeable inhibition of upstream MAP kinase kinase (MEK;
Calbiochem, San Diego, CA) (11, 25).
Cytokine ELISAs. Twenty-four hours after treatment with stimulus or without
stimulus treatment, cell culture supernatants were collected and stored at 	20°C
until assayed for TNF- production following the manufacturers’ instructions
(R&D Quantikine enzyme-linked immunosorbent assay [ELISA]; R&D Systems
Inc., Minneapolis, MN).
Flow cytometry for Toll-like receptors. Staining was performed using phyco-
erythrin (PE)-conjugated anti-human TLR1, anti-human TLR4, PE-Cy5-conju-
gated CD11b/macrophage adhesion molecule 1 (MAC-1) and fluorescein iso-
thiocyanate-conjugated TLR2 antibodies, or appropriate isotype control (BD
and eBioscience, San Diego, CA). Following antibody incubation, cells were
washed, and fixed with 4% paraformaldehyde. All incubations were performed
on ice. The total volume was adjusted to 500 l with stain buffer, and fluores-
cence was detected using the FACScan machine, collected using Cell Quest
program (Becton Dickinson), and analyzed using WinMDI version 2.9.
mRNA extraction, cDNA synthesis. and real-time PCR. RNA was extracted
using the RNeasy kit (Qiagen, Valencia, CA), following the manufacturer’s
instructions, with additional DNase treatment (Qiagen). RNA concentrations
were determined by optical density, and 100 ng of RNA was reverse transcribed
using the Advantage reverse transcription-for-PCR kit, using oligo(dT)18 primer
(BD Biosciences Clontech, San Jose, CA). Control RNA and primers were run
in parallel with test material. cDNA (1/10 final PCR volume) was used to amplify
message using the Sybr green Qiagen PCR master mix kit and an ABI 7000
machine (Foster City, CA). Cycling conditions include a hot start at 94°C for 15
min, followed by 40 to 45 cycles appropriate to primer mix. Subsequent data were
exported into the Excel package (Microsoft Office) and analyzed using a semi-
quantitative calculation (ABI), normalized against housekeeping gene (
-actin),
and statistical analysis of differences was calculated.
Western blot analysis. Whole-cell protein extracts were prepared in 200 l of
cell lysis buffer (0.1% sodium dodecyl sulfate, 62.5 mM Tris-HCl [pH 7.5], 10%
glycerol), 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail
(Sigma-Aldrich). Lysates were clarified by centrifugation at 10,000 rpm in a
refrigerated microcentrifuge for 15 min and quantified using the Lowry method
(DC protein assay; Bio-Rad, Hercules, CA). Proteins (10 to 20 g/lane) were
separated on a 10% NuPAGE bis-tris gel with morpholineethanesulfonic acid
running buffer (Invitrogen), and transferred to nitrocellulose membrane using a
Mini Trans-blot module (Bio-Rad, Hercules, CA). We detected phosphorylated
ERK (p44/42) and TLR4 using eBioscience HTA125 clone or H3 as a loading
control, using antibodies from Cell Signaling (Danvers, MA), following the
manufacturer’s guidelines. We used a chemiluminescent ECL Western blot de-
tection system (Amersham Biosciences, Piscataway, NJ) and autoradiograms
(AR film; Eastman Kodak Company, New Haven, CT). Gel images were scanned
and analyzed using Total Lab image analysis software (Nonlinear Dynamics,
Durham, NC). ERK and TLR4 signals were normalized against the housekeep-
ing protein H3. Increases in phosphorylation of ERK were calculated using ratios
of untreated and treated samples.
Statistical analysis. Data are expressed as mean values  standard errors of
the means (SEMs). Statistical significance of differences was determined using t
test (Student’s, one tailed), Kruskal-Wallis correlation tests, and Wilcoxon two-
sample tests and considered significant at P  0.05.
RESULTS
Demographics. The age of the subjects ranged from 27 to 51
years. At the time of evaluation, the CD4 counts for the HIV-
positive subjects ranged from 70 to 917 cells/mm3, and plasma
HIV RNA (viral load) ranged from 200 to 207,181 copies/ml
as determined by reverse transcription-PCR. HIV-positive
subjects were further stratified for various analyses by CD4 cell
count (200/mm3 and 200/mm3) and by viral load (10,000
copies/ml and 10,000 copies/ml). Similar results were ob-
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tained when subjects were stratified by viral load using thresh-
olds of 400 (the lower limit of detection of the assay), 1,000,
and 5,000 copies/ml. Viral loads were obtained from peripheral
blood (plasma) samples. CD4 cell counts and viral load mea-
surements were obtained within 2 to 7.5 weeks of research
bronchoscopy. All HIV-positive subjects were on HAART for
at least the past 8 months. At the time of research bronchos-
copy, some individuals were failing therapy, as indicated by
lower CD4 counts and higher viral loads. The reasons for
treatment failure were not documented but did not include any
obvious difficulties with adherence, since stable HAART for at
least the past 8 months was an inclusion requirement of the
study. Control donors were balanced for age and gender, had
negative HIV antibody at the time of participation, and no
evidence of pulmonary or systemic disease.
Altered TNF- levels in BALF samples from HIV-1-infected
individuals. Proinflammatory responses are important in pro-
tection against opportunistic infections, and TNF- is a critical
inflammatory cytokine of the innate immune system. We ex-
amined BALF fluid samples from HIV-positive individuals and
found a decrease in basal TNF- compared to healthy controls
(P  0.0135; Fig. 1A). When stratified by measures of disease
progression, TNF- production in the lung decreased with
increasing viral load and with decreasing CD4 cell counts in the
blood. Moreover, sTNFRII levels in BALF samples were sig-
nificantly greater in HIV-positive individuals (P  0.05) and
were greater with increasing viral load and decreasing CD4 cell
count. No differences in levels of sTNFRI were observed be-
tween groups (data not shown). Compared to the HIV-nega-
tive control group, this resulted in a decrease of 2.3- to 2.6-fold
in the ratio of TNF- agonist to sTNFRII antagonist activity in
the group with less advanced HIV disease (10,000 copies/ml
and 200 cells/mm3, respectively), and a decrease of 3.2- to
4-fold in the group with more advanced HIV disease who were
failing therapy (10,000 copies/ml and 200 cells/mm3, re-
spectively; Fig. 1B and C). These data show significantly al-
tered perturbations of the inflammatory cytokine TNF- and
its antagonist sTNFRII in HIV-positive individuals that are
associated with advancing HIV disease; these alterations in
TNF- and sTNFRII concentrations were noted even in sub-
jects who had responded well to HAART, which suggests per-
sistent defects in innate immune responses even in the group
with successful anti-HIV therapy.
HIV-1 infection impairs TLR-mediated TNF- production.
To determine whether decreased basal TNF- levels in BALF
samples from HIV-positive patients were associated with al-
tered TLR innate immune responses, we examined AMs from
HIV-positive individuals stimulated ex vivo with either the
TLR2 ligand Pam3Cys or the TLR4 ligand LPS. The secretion
of TNF- by AMs from HIV-positive subjects in response to
FIG. 1. (A) TNF- levels in BALF samples from asymptomatic HIV-positive subjects and healthy controls. Data are means  SEMs (error
bars) for 11 HIV-negative (HIV	) controls and 21 HIV-positive (HIV) subjects. (B) Molar ratio of TNF- to sTNFRII in BALF samples from
HIV-negative controls compared to HIV-positive subjects, stratified by HIV RNA (viral load). Data are mean  SEMs (error bars) from 9 control
subjects, 14 HIV-positive subjects with a viral load of 10,000 copies/ml, and 7 HIV-positive subjects with a viral load of 10,000 copies/ml.
(C) Molar ratio of TNF- to sTNFRII in BALF samples from HIV-negative controls compared to HIV-positive subjects, stratified by CD4 cell
count (cells/mm3). Data are means  SEMs (error bars) from 11 HIV-negative controls, 12 HIV-positive subjects with a CD4 count of 200
cells/mm3, and 5 HIV-positive subjects with a CD4 count of  200 cells/mm3. Values that were significantly different (P  0.05, Wilcoxon
two-sample test) from the value for the HIV-negative control group are indicated with an asterisk.
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both TLR ligands was decreased 1.7-fold compared with se-
cretion by AMs from healthy controls (Fig. 2). This was statis-
tically significant for the LPS-treated group, but not the
Pam3Cys-treated group, for which fewer subject samples were
available for analysis, although a similar trend was observed.
To further examine the impairment of TLR-mediated
TNF- production, we compared TNF- production by the
chronically HIV-1-infected U1 cell line to the uninfected pa-
rental U937 cell line after stimulation with increasing doses of
TLR ligand LPS or Pam3Cys for 24 h. To model AMs, U1 and
U937 cells were differentiated to an AM phenotype with PMA.
U937 cells had higher basal TNF- concentrations and pro-
duced TNF- in a dose-dependent manner in response to the
TLR2 and TLR4 ligands Pam3Cys and LPS, respectively (Fig.
3A and B, solid bars); in contrast, the HIV-1-infected U1 cells
produced minimal TNF- in response to either TLR ligand
(Fig. 3A and B, open bars). In addition, TLR-mediated TNF-
gene expression in the infected U1 cells was reduced compared
to U937 cells, in response to either Pam3Cys (Fig. 3C) or LPS
(Fig. 3D). Interestingly, there appeared to be higher basal
TNF- mRNA in U1 cells (no stimulation, P  0.059 [Fig. 3C]
and P  0.037 [Fig. 3D] by Student’s t test), although there
were lower basal protein concentrations (Fig. 3A and B, no
stimulation). However, the magnitude of response in the HIV-
1-infected U1 cells was less than that observed in the U937
cells and appeared to be TLR-ligand specific, with an increase
of fivefold in TNF- mRNA in response to the TLR2 ligand
Pam3Cys (Fig. 3C) and no increase in TNF- gene expression
in response to the TLR4 ligand LPS (Fig. 3D). In the U937
cells, there was an increase of 20-fold in TNF- mRNA in
response to both the TLR2 and TLR4 ligands. Moreover, this
TLR-induced TNF- expression was inhibited by pretreatment
of cells with the ERK inhibitor PD98059, as manifested by
decreased TNF- mRNA and subsequent protein production
FIG. 2. TLR-induced TNF- production by alveolar macrophages
from HIV-negative (HIV	) healthy volunteers (solid bars) or HIV-
positive (HIV) subjects (open bars) stimulated with 100 ng/ml LPS
or 10 ng/ml Pam3Cys (PAM) for 24 h. Data are means  SEMs (error
bars). Values that were significantly different from the value for the
control group (HIV	) are indicated as follows: *, P  0.05 by t test;
†, P  0.05 by Wilcoxon two-sample test. NS, no stimulation (me-
dium alone).
FIG. 3. TNF- induction by TLR ligands in U937 cells (solid bars) and HIV-1-infected U1 cells (open bars). Cells were differentiated with 10
nM PMA for 24 h, washed, and then incubated with Pam3Cys (PAM) (A and C) or LPS (ng/ml) (B and D) for 24 h. TNF- protein (A and B)
was measured by ELISA, and gene expression (C and D) was measured by real-time PCR. ERK phosphorylation was blocked by 45 min
pretreatment with 25 M PD98059 (PD) and then cells were treated with TLR ligand for 24 h. Each test was carried out in duplicate. Data are
means plus SEMs (error bars) and are representative of three independent experiments. Values that that were significantly different (P  0.05
by t test) from the value for the control group (HIV	) are indicated by an asterisk. NS, no stimulation (medium alone).
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(protein data not shown). Taken together, the patient AM and
cell line data confirm that HIV-1-infection alters the ability of
TLR ligands to induce TNF- production, which may result in
a compromised innate immune response.
Decreased expression of TLR1 and TLR4 on HIV-1-infected
cells. Because Pam3Cys and LPS led to reduced TNF- pro-
duction in AMs from HIV-positive subjects and in HIV-1-
infected cells, we examined the cell surface expression of TLR1
(which forms heterodimers with TLR2), TLR2 (the receptor
for Pam3Cys), and TLR4 (the receptor for LPS) on U937 and
U1 cells. TLR1, TLR2, and TLR4 were present on both unin-
fected U937 and HIV-1-infected U1 cells; however, surface
expression of TLR1 and TLR4, but not TLR2, were reduced in
the U1 cells (Fig. 4B) compared to the uninfected parental cell
line, U937 (Fig. 4A). We also examined TLR6, which signals
with TLR2 in response to mycobacteria, and found no signif-
icant differences in expression between cell types (data not
shown). Of note, TLRs were predominately detected on cells
that showed an activated phenotype as determined by CD11b/
MAC-1 staining. The majority of HIV-positive U1 cells (96%)
were found to be CD11b/MAC-1 positive, compared to ap-
proximately 34% of the uninfected U937 cells. Both cell lines
were pretreated with equal concentrations and duration of
PMA; therefore, the presence of HIV is likely playing a role in
the increased activation state of the U1 cells. Western blot
analysis also showed decreased levels of TLR4 protein in HIV-
positive U1 cells (Fig. 4C).
Reduced responses to TLR ligands could be explained by
decreased surface expression of TLRs and decreased expres-
sion of TLR4 protein in the HIV-1-infected U1 cells. Consis-
tent with these observations in a HIV-infected cell line, we also
observed a downregulation of TLR gene expression in AMs
from HIV-positive individuals compared to healthy controls
(Fig. 4D). This difference was statistically significant for the
TLR1 and TLR2 genes (P  0.05), for which a difference of
1.5- to 1.8-fold was observed. Although the difference in TLR4
gene expression was not significantly different between HIV-
positive and HIV-negative healthy controls, there was a trend
toward less TLR4 in the HIV-positive AMs. We did not mea-
sure TLR surface expression on AMs by fluorescence-activated
cell sorting (FACS) because of insufficient cell numbers for
many study subjects after other experiments were performed.
These data suggest that the decreased TNF- response to
TLR2 and TLR4 ligands in AMs from HIV-positive subjects
may be due to reduced TLR gene and receptor expression.
Reduced phosphorylated ERK in response to TLR ligands
in infected promonocytic cells. Phosphorylation of ERK is
involved in many critical signaling pathways and is required for
the production of TNF- protein in response to TLR ligands
(25). To assess the role of ERK in TLR2 and TLR4 signaling
during HIV infection, we cultured AMs and U937 and U1 cells
in the presence and absence of the MAP kinase inhibitor
PD98059, an upstream inhibitor of ERK phosphorylation, fol-
lowed by Pam3Cys or LPS treatment. Protein extracts were
analyzed by Western blotting for phosphorylated ERK. We
used the H3 protein as a control, since the expression of this
protein was not influenced by TLR signaling or HIV-1 infec-
tion.
When we examined cytoplasmic protein extracts from HIV-
positive AMs and healthy volunteers for the presence of phos-
phorylated ERK in response to the TLR4 ligand LPS, we
found decreased activation of ERK in the HIV-positive AMs
compared to uninfected AMs (Fig. 5A). In cell lines, Western
blot data showed an increase of two- to threefold in phosphor-
ylated ERK in the uninfected U937 cells detected up to 60 min
in response to both TLR2 and TLR4 ligands. These responses
were inhibited by pretreatment of the cells with PD98059 (Fig.
5B and C). In contrast, in the infected U1 cells, increased basal
levels of phosphorylated ERK were observed, but there was no
significant induction of phosphorylation through 60 min in
response to either Pam3Cys (Fig. 5B) or LPS (Fig. 5C). U1
cells showed minimal activation of ERK in response to either
ligand, and treatment with the inhibitor did not significantly
decrease phosphorylation of ERK. Therefore, unlike U937
cells, the HIV-1-infected U1 cells did not induce further sig-
naling upon treatment with TLR ligands. In U1 cells, there
were higher basal levels of ERK, which was associated with
dampened responses to TLR2 and TLR4 ligands; this may in
part explain decreased TNF- production. Therefore, altered
signaling through ERK in the HIV-1-infected cell lines and
AMs from HIV-positive subjects was associated with de-
creased inflammatory cytokine production in response to LPS
and Pam3Cys.
DISCUSSION
Most studies of host immunity against HIV and opportunis-
tic pathogens that affect HIV-positive individuals have focused
on the adaptive immune response. Less is known about the
more primitive innate immune response during HIV infection.
In this study, we examined BALF samples and alveolar mac-
rophages from HIV-positive subjects and healthy matched
HIV-negative control subjects. We extended our investigation
using the PMA-differentiated monocyte cell line U937 (23)
and its HIV-1-infected subclone U1 to mimic an AM pheno-
type. We determined cell membrane expression of TLR1,
TLR2, and TLR4 and found decreased surface expression of
TLR1 and TLR4 on the HIV-1-infected U1 cell line as well as
decreased TLR4 protein compared to the uninfected U937
cells. Due to low cell numbers obtained from bronchoalveolar
lavage in this study group, we were unable to perform FACS
for TLR surface expression on AMs, although results from
real-time PCR showed decreased gene expression of a subset
of TLRs (Fig. 4D). We also found significantly less production
of TNF- in response to TLR2 and TLR4 ligands in U1 cells
and in AMs from HIV-positive subjects (TLR4 ligand) and a
trend toward decreased responses to the TLR2 ligand in AMs
from HIV-positive subjects, for which fewer samples from
study subjects were available for analysis (Fig. 2).
Studies have shown that HIV infection quickly depletes in-
testinal lymphoid tissues and compromises mucosal integrity
(6). This leads to “microbial translocation” and the presence of
bacterial products in the peripheral circulation. These bacterial
products include LPS from gram-negative bacteria and pepti-
doglycan, the naturally occurring TLR2 ligand analog of
Pam3Cys from gram-positive bacteria that colonize the normal
human intestine. Thus, the TLR ligand responses we studied
have direct relevance to persons with HIV infection. Brenchley
(5) and others have shown that plasma levels of LPS correlate
with chronic immune activation of CD4 cells; this may lead to
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FIG. 4. Flow cytometric analysis of TLR1, TLR2, and TLR4 constitutive surface expression on PMA-pretreated (10 nM for 48 h) U937 (A) and
U1 (B) cells. Cells were labeled with PE-Cy5-conjugated CD11b/MAC-1 antibody, PE-conjugated TLR1 (left), fluorescein isothiocyanate-
conjugated TLR2 (middle), or PE-conjugated TLR4-PE (right) antibody or matched isotype control. Cells were gated on CD11b/MAC-1-positive
cells. Thirty-four percent of U937 cells and 97% of HIV-positive U1 cells were CD11b/MAC-1 positive. Representative histograms show isotype
(shaded) or test antibody (black line). The percentage of positive cells for test antibody and the geometric mean fluorescence intensity in
parentheses are shown for each graph in panels A and B. Samples were collected by FACS and analyzed with WinMDI version 2.9 software.
(C) Whole-cell protein extracts from cell lines pretreated with PMA were analyzed by Western blotting for the presence of TLR4 and control
protein H3. We used densitometry and the Total Lab computer package to determine band intensities and normalized the TLR4 band with control
H3 for no stimulation (NS) and LPS treatment (in minutes) for U937 (solid bars) and U1 (open bars) cells. The height of the triangle above the
gel shows the increasing amount of time after LPS treatment. (D) Total RNA from HIV-negative healthy volunteers (n  4; solid bars) and
HIV-positive (n  5; open bars) alveolar macrophages was used to perform two-step real-time PCR analysis. Data are mean relative mRNAs plus
SEMs (error bars), normalized using the 
-actin housekeeping gene. Values for HIV-positive AMs that were significantly different from the value
for HIV-negative AMs are indicated as follows: *, P  0.05 by t test.
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T-cell activation, increased entry into the cell cycle, and ulti-
mately increased death of central memory CD4 cells, which is
one of the hallmarks of the immunodeficiency associated with
HIV infection (N. T. Funderburg, A. Luciano, W. Jiang, S.
Sieg, and M. Lederman, presented at the Fourth International
Conference on HIV Pathogenesis, Treatment, and Prevention,
Sydney, Australia, 22 to 25 July 2007). Our data concerning the
effects of LPS on innate immune function through TLR4 in-
FIG. 5. (A) Cytoplasmic protein extracts from HIV-positive (HIV) AMs (n  3; patient 5 [P5] to P7) and HIV-negative (HIV	) healthy
volunteers (n  4; P1 to P4) were analyzed by Western blotting for the presence of phosphorylated ERK (pERK) (p42/44) and control protein
H3. We used densitometry and the Total Lab computer package to determine band intensities and normalized the phosphorylated ERK p42 band
with control H3 (shown in graph) for no stimulation (NS) and LPS treatment. (B and C) Differentiated U937 cells (solid line) and U1 cells (dashed
line) were treated with () either Pam3Cys (PAM) (10 ng/ml) (B) or LPS (100 ng/ml) (C) for 15, 30, or 60 min with () or without (	) 30 min
pretreatment with the ERK inhibitor PD98059 (PD) (25 M). We analyzed Western blots on whole-cell lysates by densitometry, and increases in
phosphorylation of ERK were determined from ratios of normalized treatment over no stimulation (NS).
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dicate that similar mechanisms may be pertinent in vivo
through microbial translocation.
Viral infection can cause alterations in TLR4 protein ex-
pression and membrane localization, altering the lung environ-
ment and innate immune responses, with a subsequent switch
from an LPS-tolerant state to a LPS-responsive state (4, 22, 27,
34). Several HIV-1 accessory proteins have been implicated in
the regulation of TLR expression and signaling (24). HIV-1
Nef protein altered TLR-dependent cytokine production in
AMs from HIV-positive subjects through induction of cellular
phosphatases and inhibition of intracellular signaling (35).
HIV may utilize multiple strategies to alter TLR expression
and signaling, and these effects may vary based on cell type and
location. Heggelund et al. (14) showed enhanced expression of
TLR2 (but not TLR4) on peripheral blood monocytes from
HIV-positive subjects after exposure to the HIV-1 envelope
protein gp120. Effects on TLR expression may vary in relation
to the macrophage type (from different body compartments);
specifically, AMs may differ from peripheral blood monocytes
in terms of TLR expression during HIV infection. Reports of
the expression of TLRs on U1 cells have also varied (29, 35),
perhaps due to differences in experimental procedures and
conditions, such as the concentration of the PMA used or the
cell passage number. We have also shown that more U1 cells
become activated, as measured by CD11b/MAC-1 expression,
than U937 cells after PMA stimulation, and that the majority
of TLR expression occurs on these activated cells. Further
studies to determine the role of macrophage maturation on
TLR expression and signaling will be of interest.
TNF- is a cytokine which has pleiotropic biological actions,
and since cytokines act locally, examining concentrations in
specific organs, such as the lung, is important. The balance of
TNF- with antagonist moieties, such as sTNFRII, determines,
in part, net agonist activity of TNF-, since sTNFRII acts as a
“scavenger” for TNF-. The balance of TNF- and sTNFRII
in the lung likely determines innate immune function, rather
than plasma concentrations as measured in other studies (15,
16, 31). In our study, the ratio of TNF- to sTNFRII was
lowest in the groups with the highest viral load and lowest CD4
cell count; higher ratios indicate more abundant agonist
TNF- activity, which we postulate is associated with normal
innate immune function in the lung. Anti-TNF- therapies
highlight the importance of TNF- in normal host innate im-
munity, since their use in Crohn’s disease (18) and rheumatoid
arthritis (21) is associated with an increased incidence of my-
cobacterial and other bacterial infections, especially in the lung
(32, 37).
Although sTNFRII “scavenges” soluble TNF- and limits
binding to surface receptors, thereby acting as an inhibitor, it has
also been shown to stabilize TNF-, preserving its activity and
potentially augmenting longer-term effects (2). It may be that
stabilizing TNF- in compartments, such as alveolar spaces,
where the clearance of TNF- is already slow (28), may have
significant biological consequences. The absolute amounts of
TNF- in BALF may not be as significant as the relationship
between sTNFRII and its stability in the lung environment, which
could lead to persistently abnormal innate immune function.
Cytokines also play a role in TLR signaling through alter-
ations in expression of TLRs. TNF- and IFN- regulate
TLR4 expression in intestinal epithelial cells (1) and TLR4 in
monocytes and macrophages (3). This makes biologic sense,
since tight control of inflammatory responses at mucosal sur-
faces, which are exposed to commensal bacteria and exogenous
agents, would be beneficial to host defense. In addition to
decreased TNF- production by AMs exposed to Pam3Cys or
LPS, we also observed decreased responses in other pathways
involved in TLR-induced TNF- production, such as NF-B
p50 nuclear translocation (data not shown) and TNF- gene
expression. Moreover, there was decreased phosphorylation of
ERK in AMs from HIV-positive subjects and infected cell
lines. It is interesting to note there were increased basal (con-
stitutive) levels of phosphorylated ERK in the U1 cell line and
subsequent lower increases in response to TLR ligands, which
may indicate that chronic stimulation of TLRs may “tolerize”
their receptors and lead to defective TLR signaling and innate
immune responses. This concept is supported by the observa-
tion of deficits in TLR-dependent TNF- production in U1
cells that were almost all in the activated state as measured by
CD11b/MAC-1 staining (Fig. 3). Further studies will be re-
quired to determine whether decreased phosphorylation of
other MAP kinases, such as p38 and Jun N-terminal protein
kinase, in response to HIV infection, is also evident.
Taken together, our studies show altered TLR-dependent
innate immune responses of AMs from HIV-positive subjects
and in HIV-1-infected cell lines. In future studies, it will be
important to determine the effects of other TLR ligands on
innate immune responses and whether altered surface receptor
expression involves changes in transcription, translation, or
membrane transport of TLRs. Our findings of altered patho-
gen recognition receptors and lower innate immune responses,
through indirect cytokine or direct viral protein effects, may
help explain the increased occurrence of OIs and other pul-
monary infections in HIV-positive individuals.
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